This article is for informational purposes only and is not a substitute for professional medical advice. Always talk to your prescriber before making changes to your treatment. If you experience severe symptoms, call emergency services immediately. See our full medical disclaimer.

Ozempic (semaglutide) side effects are dominated by the gastrointestinal system. In placebo-controlled trials submitted to the FDA, nausea affected roughly 16–20% of patients on therapeutic doses, diarrhea around 8–9%, and vomiting up to 9%. The good news: these effects occur mainly during dose escalation and typically ease with time. Serious adverse events including pancreatitis and gallbladder disease do appear in the data, but at much lower rates. The drug carries an FDA boxed warning about thyroid C-cell tumors seen in rodents, though no causal link in humans has been established.

Key Takeaways

  • Nausea, vomiting, diarrhea, constipation, and abdominal pain are the most common Ozempic side effects, affecting 3–20% of patients depending on the symptom and dose.
  • GI symptoms peak during dose escalation and most reports resolve as the body adjusts at a stable dose.
  • About 3.1–3.8% of patients in placebo-controlled trials stopped treatment due to GI side effects, versus 0.4% on placebo.
  • Serious but uncommon risks include acute pancreatitis and gallbladder disease (gallstones, cholecystitis).
  • A boxed warning covers thyroid C-cell tumors seen in rodents. The drug is contraindicated in anyone with a personal or family history of MTC or MEN2.
  • Hypoglycemia risk is low when Ozempic is used alone, but rises when combined with sulfonylureas or insulin.

How Ozempic Works and Why GI Side Effects Are Built In

To understand why the stomach is the main trouble zone, you need to understand the drug’s mechanism. Ozempic is a GLP-1 receptor agonist, a class explained in depth in our guide to how GLP-1 drugs work. Semaglutide mimics a gut hormone that slows gastric emptying, meaning food stays in the stomach longer. This is part of how it reduces appetite and blood sugar spikes. But slowing gastric emptying also causes nausea, a sensation of fullness that arrives quickly, and the downstream effects of undigested food moving through the intestines at an altered rate.

This is not a quirk or a manufacturing defect. The GI effects are a direct pharmacological consequence of the drug doing exactly what it is designed to do. The clinical trials were designed in part to measure how tolerable that tradeoff is.

Common Ozempic Side Effects: What the Trial Data Actually Shows

The adverse reactions table in the FDA prescribing information for Ozempic draws from a pool of placebo-controlled trials. The figures below come from that source and reflect patients with type 2 diabetes on therapeutic doses.

Gastrointestinal Side Effects by Dose

Side EffectPlaceboOzempic 0.5 mgOzempic 1 mg
Nausea6.1%15.8%20.3%
Diarrhea1.9%8.5%8.8%
Vomiting2.3%5.0%9.2%
Abdominal pain4.6%7.3%5.7%
Constipation1.5%5.0%3.1%
Source: FDA Ozempic Prescribing Information. Placebo-controlled trial pool, patients with type 2 diabetes.

Overall, GI adverse reactions occurred in 32.7% of patients on 0.5 mg and 36.4% on 1 mg, versus 15.3% on placebo, according to the FDA label. That gap is real, but context matters: most of these events were mild to moderate in severity. Severe GI adverse reactions were reported in only 0.4% (0.5 mg) and 0.8% (1 mg) of patients.

Regarding timing: the FDA label states that the majority of nausea, vomiting, and diarrhea reports occurred during dose escalation periods, not after patients reached a stable maintenance dose. A 2023 safety analysis published in Diabetes, Obesity and Metabolism (Aroda et al.) covering the full SUSTAIN and PIONEER phase IIIa programs confirmed that GI discontinuations mostly happened early in treatment and during titration.

How Many Patients Actually Stopped Treatment?

Discontinuation due to GI adverse reactions occurred in 3.1% of patients on 0.5 mg and 3.8% on 1 mg, compared with 0.4% on placebo. These figures are from the FDA-reviewed trial pool. A broader analysis across the SUSTAIN program placed the GI discontinuation rate at approximately 7.8% for semaglutide versus 3.0% for comparators, reflecting the longer follow-up periods in some trials. Either way, the majority of patients who started Ozempic stayed on it through the GI adjustment phase.

Dose Escalation: The Main Tool for Managing GI Side Effects

The standard Ozempic initiation protocol starts at 0.25 mg once weekly for four weeks. That dose is not intended to lower blood sugar; it exists solely to let the body acclimate. After four weeks, the dose increases to 0.5 mg. From there, a prescriber may advance to 1 mg or, more recently approved, 2 mg, each step separated by at least four weeks.

If GI symptoms are poorly tolerated at any step, the FDA label explicitly allows delaying the next dose increase by an additional four weeks. Slowing the titration schedule does not compromise the drug’s eventual effectiveness, and many clinicians consider it the first-line response to early nausea rather than discontinuing the drug entirely.

Practical strategies reported in prescribing guidance and clinical practice include eating smaller meals, stopping when full rather than finishing the plate, staying well hydrated, and avoiding fatty or spicy foods during the first weeks of a new dose level. These measures do not cure nausea, but they reduce its intensity for most patients.

Serious Warnings: What to Watch For

Serious adverse events are less common but are documented in the prescribing information and require attention.

Pancreatitis

Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing cases, has been observed in patients taking GLP-1 receptor agonists including semaglutide. The FDA label instructs prescribers to discontinue Ozempic if pancreatitis is confirmed and not to restart it. Importantly, the SUSTAIN-6 cardiovascular outcomes trial (Marso et al., NEJM, 2016) found pancreatitis in 9 patients in the semaglutide group versus 12 in the placebo group, a result that did not establish a causal signal in that study population. The precaution remains on the label because a causal relationship across the drug class cannot be ruled out, and because pancreatitis is a serious condition that warrants clinical vigilance.

Symptoms to report promptly: severe, persistent abdominal pain that radiates to the back, sometimes with nausea or vomiting.

Gallbladder Disease

The FDA label for Ozempic notes an association with acute gallbladder disease, including gallstones (cholelithiasis) and gallbladder inflammation (cholecystitis). In placebo-controlled trials, cholelithiasis was reported in 1.5% of patients on 0.5 mg and 0.4% on 1 mg, while it was not reported in the placebo group in those same trials. In a separate long-term cardiovascular outcomes trial, gallstone rates were similar between semaglutide (1.1%) and placebo (0.9%) groups.

The mechanism is not fully established, but rapid weight loss is a known independent risk factor for gallstone formation regardless of how the weight loss is achieved. Patients with existing gallbladder risk factors should discuss this with their prescriber.

Thyroid C-Cell Tumor Warning (Boxed Warning)

Ozempic carries the FDA’s most prominent alert type, a boxed warning, for thyroid C-cell tumors. In lifetime carcinogenicity studies, rats and mice given semaglutide developed C-cell hyperplasia and thyroid tumors, including medullary thyroid carcinoma, at doses that overlapped with human therapeutic exposures.

The key scientific nuance: rodents have a substantially higher density of GLP-1 receptors in thyroid C-cells than humans do. This biological difference is why the FDA label states directly that “it is unknown whether OZEMPIC causes thyroid C-cell tumors, including MTC, in humans.” A 2025 large-scale observational analysis of over 350,000 patients did not find a statistically significant increase in thyroid cancer risk with GLP-1 medications in humans. But because the human relevance has not been definitively resolved, the contraindication stands.

Ozempic is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN2). For everyone else, the current human evidence does not support routine thyroid cancer screening solely because of Ozempic use, but any lump in the neck, persistent hoarseness, or difficulty swallowing should prompt a call to your prescriber.

Hypoglycemia: Context-Dependent Risk

Semaglutide stimulates insulin secretion in a glucose-dependent manner, meaning the effect tapers off when blood sugar is already low. Because of this mechanism, Ozempic used alone carries a relatively low intrinsic risk for hypoglycemia in patients with type 2 diabetes.

That picture changes when Ozempic is combined with other glucose-lowering drugs. Patients taking it alongside sulfonylureas or insulin face a meaningfully higher risk of low blood sugar episodes. The FDA label recommends reducing the dose of the concomitant insulin secretagogue or insulin when starting Ozempic to lower that risk. Anyone on combination therapy should know the signs of hypoglycemia: shakiness, sweating, confusion, rapid heartbeat, and hunger.

Other Warnings in the FDA Label

  • Acute kidney injury: Severe vomiting or diarrhea can lead to dehydration and reduced kidney function. Patients with existing kidney disease need closer monitoring.
  • Diabetic retinopathy complications: Rapid glycemic improvement has been associated with short-term worsening of retinopathy in patients with pre-existing retinopathy; the label recommends monitoring.
  • Hypersensitivity reactions: Serious allergic reactions including anaphylaxis and angioedema have been reported. Discontinue Ozempic and seek care immediately if signs of a serious allergic reaction occur.
  • Heart rate increase: A small mean increase in resting heart rate (approximately 1–6 beats per minute) has been observed across GLP-1 receptor agonist trials. Clinical significance for most patients is uncertain, but patients with pre-existing cardiac conditions should discuss this finding with their cardiologist.

A Note on Muscle Loss and Body Composition

One adverse effect that does not appear prominently in the GI-focused adverse events table but deserves discussion is muscle loss. Weight reduction from any cause tends to include some loss of lean mass, and Ozempic is no exception. This is covered in detail in our analysis of muscle loss with GLP-1 medications. Resistance exercise and adequate protein intake are the primary strategies clinicians recommend to preserve lean mass during treatment.

Putting the Risk Profile in Perspective

Reading an adverse events table in isolation can be misleading. The patients enrolled in the SUSTAIN trials had type 2 diabetes, many with established cardiovascular disease or chronic kidney disease. They were already at high baseline risk for multiple complications. The GI side effects are real, numerically common, and a legitimate reason some patients do not continue the drug. The serious warnings, particularly pancreatitis and gallbladder disease, are medically meaningful even at low incidence rates and should not be dismissed.

At the same time, the SUSTAIN-6 trial found a 26% reduction in the composite risk of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death in patients on semaglutide versus placebo. That context matters when weighing GI discomfort during titration against potential cardiovascular benefit in appropriate patients. That benefit-risk evaluation belongs between a patient and their prescriber, not in a table of raw percentages.

Frequently Asked Questions

What is the most common side effect of Ozempic?

Nausea is the most frequently reported side effect of Ozempic (semaglutide). In FDA-reviewed placebo-controlled trials, nausea occurred in 15.8% of patients on the 0.5 mg dose and 20.3% on the 1 mg dose, compared with 6.1% on placebo. Most cases were mild to moderate and occurred during dose escalation rather than throughout the full treatment period.

Does Ozempic cause thyroid cancer in humans?

There is currently no confirmed evidence that Ozempic causes thyroid cancer in humans. The FDA boxed warning is based on rodent studies showing dose-dependent thyroid C-cell tumors. Rodents have a higher density of GLP-1 receptors in thyroid C-cells than humans, and large human observational studies have not found a statistically significant increase in thyroid cancer risk. The drug is contraindicated in people with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN2).

How long do Ozempic side effects last?

Most gastrointestinal side effects are most intense during the first weeks of treatment and during each dose escalation step. According to the FDA label, the majority of nausea, vomiting, and diarrhea reports occurred during the dose-escalation phase. For many patients, symptoms subside as the body adjusts, usually within 4 to 8 weeks at a stable dose. Slowing the escalation schedule under a prescriber’s guidance often reduces severity.

Can Ozempic cause low blood sugar on its own?

Ozempic alone is a low-risk drug for hypoglycemia because it stimulates insulin secretion in a glucose-dependent manner, meaning it slows down when blood sugar is already low. However, hypoglycemia risk rises significantly when Ozempic is combined with other glucose-lowering medications such as sulfonylureas or insulin. In those cases, the FDA label recommends reducing the dose of the concomitant medication.

Sources

  • U.S. Food and Drug Administration. Ozempic (semaglutide) Prescribing Information. accessdata.fda.gov. Reviewed 2023–2025.
  • Marso SP, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6). New England Journal of Medicine. 2016;375(19):1834-1844. doi:10.1056/NEJMoa1607141.
  • Aroda VR, et al. Safety and tolerability of semaglutide across the SUSTAIN and PIONEER phase IIIa clinical trial programmes. Diabetes, Obesity and Metabolism. 2023;25(3):543-558. doi:10.1111/dom.14990.
  • National Center for Biotechnology Information. Semaglutide. StatPearls. ncbi.nlm.nih.gov/books/NBK603723/. Updated 2024.
  • Roswell Park Comprehensive Cancer Center. Ozempic and thyroid cancer. roswellpark.org. September 2024.

Sources